Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Enterprise Value (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Enterprise Value for 16 consecutive years, with -$81.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 2.46% to -$81.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$81.2 million, a 2.46% decrease, with the full-year FY2025 number at -$81.2 million, down 2.46% from a year prior.
  • Enterprise Value was -$81.2 million for Q4 2025 at Anika Therapeutics, down from -$80.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$75.4 million in Q1 2025 to a low of -$124.2 million in Q4 2021.
  • A 5-year average of -$99.3 million and a median of -$96.9 million in 2021 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 32.69% in 2021, then crashed 34.04% in 2022.
  • Anika Therapeutics' Enterprise Value stood at -$124.2 million in 2021, then increased by 2.64% to -$121.0 million in 2022, then rose by 21.38% to -$95.1 million in 2023, then grew by 16.7% to -$79.2 million in 2024, then fell by 2.46% to -$81.2 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Enterprise Value are -$81.2 million (Q4 2025), -$80.2 million (Q3 2025), and -$77.1 million (Q2 2025).